ArticleCell death discovery2026
TRPV4 mediates aminoglycoside trafficking and ototoxicity without compromising antimicrobial efficacy.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HDAC1 Represses NRF2 Transcription via H3K27ac Remodeling to Aggravate Neomycin-Induced Cochlear Hair Cell Damage.Neurochemical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Aminoglycoside (AG) antibiotics remain essential for treating life-threatening infections; however, their clinical use is limited by irreversible ototoxicity. The mechanisms of AG entry into the cochlea and its role in cochlear degeneration remain unclear. This study identified the transient receptor potential vanilloid 4 (TRPV4) channel as a key mediator of AG trafficking and ototoxicity. In an AG-induced ototoxicity mouse model, TRPV4 pharmacological inhibition reduced cochlear AG accumulation, preserving hearing, hair cell (HC) survival, and cochlear synaptic integrity. Conversely, TRPV4 pharmacological activation accelerated cochlear AG influx, exacerbating AG-induced ototoxicity. Cochlear explant experiments showed that TRPV4 agonists and antagonists modulated Texas Red-labeled gentamicin uptake and HC survival, suggesting that TRPV4 directly contributes to the regulation of HC permeability and survival in the explant preparation. Notably, TRPV4 modulation did not compromise AG antimicrobial activity in bacterial-killing assays, uncoupling therapeutic efficacy from ototoxicity. Collectively, these findings identify TRPV4 as a molecular gateway for AG trafficking into cochleae and demonstrate that its inhibition offers a strategy to protect hearing while maintaining antimicrobial potency. Thus, targeting TRPV4 may provide a clinically translatable approach to prevent AG-induced ototoxicity without undermining their life-saving benefits.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.